RATINGS CHANGES 

Comerica (CMA - Get Report) was upgraded to neutral from underperform at Bank of America/Merrill Lynch. $70 price target. The company has strong earnings leverage to higher interest rates, analysts said. 

Brinker (EAT - Get Report) was downgraded to underperform at BMO Capital. The valuation is less attractive, based on a $45 price target. 

Flowers Foods (FLO - Get Report) was upgraded to equal-weight from sector weight at Keybanc. $23 price target. Expect more settlements and cost-cutting efforts from the company, Keybanc said. 

General Mills (GIS - Get Report)  was downgraded to sector perform from outperform at RBC Capital. $69 price target. Earnings estimates were also cut, given accelerating volume declines, RBC said. 

Heico (HEI - Get Report) was upgraded to outperform from neutral at Credit Suisse. $86 price target. The company generates consistent free-cash flow, which should be augmented by recent acquisitions, Credit Suisse said. 

Halyard (HYH) was downgraded to hold from buy at Deutsche Bank. $35 price target. 2017 will likely be another transitional year, Deutsche said. 

Instructure (INST - Get Report) was initiated as a sell at TheStreet Ratings. You can view the full analysis from the report here: INST.

MasterCard (MA - Get Report) was upgraded to buy at Bank of America/Merrill Lynch. $120 price target. The company is a consistent grower and deserves a premium valuation, analysts said. 

M&T Bank (MBT - Get Report) was downgraded to underperform from neutral at Bank of America/Merrill Lynch. $155 price target. The company has limited relative earnings upside potential, analysts said. 

Stifel Financial (SF - Get Report) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: SF.

Swift (SWFT) was upgraded to overweight from neutral at J.P. Morgan. $31 price target. The company is leveraged to a turn in the truckload cycle, J.P. Morgan said. 

Univar (UNVR - Get Report) was upgraded to outperform from market perform at Wells Fargo. The company can improve execution, despite a muted sales environment, Wells said. 

Visa (V - Get Report) was upgraded to buy at Bank of America/Merrill Lynch. $92 price target. The company can deliver consistent growth and deserves a premium valuation, analysts said. 

Valeant Pharmaceuticals (VRX) was downgraded to equal-weight from overweight at Morgan Stanley. $17 price target. Earnings estimates were also cut, given weaker business trends, Morgan said. 

This article was written by a staff member of TheStreet.